Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 14/07/2025 pm IST			5-day change	1st Jan Change
443.25 ^DKK	+0.98%		-1.78%	-28.99%

14/07	Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	FW
14/07	Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	MT

US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list

Published on 18/06/2025 at 20:59, updated on 20/06/2025 at 20:07

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	14/07	FW
Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	14/07	MT
Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	14/07	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	11/07	RE
FDA May Fast Track Drug Reviews for Lower US Prices	11/07	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	11/07	MT
NOVO NORDISK : Gets a Buy rating from UBS	11/07	ZD
Wall Street Waits to Hear the Numbers	11/07
Mining, healthcare prop up European shares; US-EU trade talks in focus	10/07	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	09/07	RE
European shares close at four-week high on banks boost; US trade talks in focus	09/07	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	09/07	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	09/07	ZD
Europe rises despite new US tariff mayhem	09/07	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	08/07	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	08/07	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	08/07	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	08/07	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	08/07	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	08/07	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release

More about the company